PMID- 18512268
OWN - NLM
STAT- MEDLINE
DCOM- 20080930
LR  - 20131121
IS  - 1932-6254 (Print)
IS  - 1932-6254 (Linking)
VI  - 2
IP  - 5
DP  - 2008 Jul
TI  - Desferrioxamine-driven upregulation of angiogenic factor expression by human bone 
      marrow stromal cells.
PG  - 272-8
LID - 10.1002/term.92 [doi]
AB  - Bone marrow stromal cells (BMSCs) are the subject of intense research because of 
      their biological properties and potential use for the repair of damaged tissues. 
      Success of BMSC-based therapies, however, relies on a number of methodological 
      improvements, including the establishment of a vascular network providing 
      nutrients and oxygen to the transplanted cells and ensuring their immediate 
      survival and long-term functionality. We described a method to enhance the 
      autocrine expression of angiogenic factors by BMSCs. For this purpose, human 
      BMSCs were treated with desferrioxamine (DFX). No PDGF-BB, VEGF-R1 or -R2 mRNA 
      expression was detected under any of the conditions tested. mRNA and protein 
      expression levels of TGFbeta1 were similar in BMSCs, whether they were exposed to 
      DFX (50 microM) or to control conditions under normoxia for 48 h. In comparison 
      with the results obtained with control conditions under normoxia, exposure of 
      BMSCs to DFX for 48 h resulted in upregulation of bFGF at the protein (26-fold) 
      but not at the mRNA levels and VEGF at both the mRNA (1.5-fold) and protein 
      levels (4.5-fold). In comparison with the results obtained with control 
      conditions under hypoxia, DFX induced a 50% increase in VEGF secretion but led to 
      the same level of hypoxia inducible factor-1alpha protein expression (a 
      transduction factor involved in angiogenic factor expression and known to be 
      activated by DFX). Exposure of BMSCs to DFX resulted in oversecretion of 
      angiogenic factors, suggesting that DFX-treated BMSCs could be used to supply 
      angiogenic factors.
CI  - 2008 John Wiley & Sons, Ltd
FAU - Potier, Esther
AU  - Potier E
AD  - Universite Denis Diderot Paris VII, Laboratoire de Recherches Orthopediques 
      (B2OA), UMR CNRS 7052, Paris, France. esther.potier@gmail.com
FAU - Ferreira, Elisabeth
AU  - Ferreira E
FAU - Dennler, Sylviane
AU  - Dennler S
FAU - Mauviel, Alain
AU  - Mauviel A
FAU - Oudina, Karim
AU  - Oudina K
FAU - Logeart-Avramoglou, Delphine
AU  - Logeart-Avramoglou D
FAU - Petite, Herve
AU  - Petite H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Tissue Eng Regen Med
JT  - Journal of tissue engineering and regenerative medicine
JID - 101308490
RN  - 0 (Angiogenesis Inducing Agents)
RN  - 0 (DNA Primers)
RN  - 0 (RNA, Messenger)
RN  - J06Y7MXW4D (Deferoxamine)
SB  - IM
MH  - Angiogenesis Inducing Agents/*metabolism
MH  - Base Sequence
MH  - Bone Marrow Cells/cytology/*metabolism
MH  - DNA Primers
MH  - Deferoxamine/*pharmacology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - RNA, Messenger/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stromal Cells/cytology/*metabolism
MH  - Up-Regulation/*drug effects
EDAT- 2008/05/31 09:00
MHDA- 2008/10/01 09:00
CRDT- 2008/05/31 09:00
PHST- 2008/05/31 09:00 [pubmed]
PHST- 2008/10/01 09:00 [medline]
PHST- 2008/05/31 09:00 [entrez]
AID - 10.1002/term.92 [doi]
PST - ppublish
SO  - J Tissue Eng Regen Med. 2008 Jul;2(5):272-8. doi: 10.1002/term.92.